NRIX — Nurix Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1549595 ·
Last close
$22.21
Market Cap
$2.30B
52W High
$28.23
52W Low
$9.00
ADV30
1,484,813
Next earnings
2026-10-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | 9,043,000 | — | -94,204,000 | -89,535,000 | 535,540,000 | 67,685,000 | 132,913,000 |
| Feb 2026 | 6,252,000 | — | -92,495,000 | -87,174,000 | 636,130,000 | 71,195,000 | 155,237,000 |
| Nov 2025 | 13,577,000 | — | -83,095,000 | -78,221,000 | 688,135,000 | 246,960,000 | 149,388,000 |
| Aug 2025 | 7,894,000 | — | -91,385,000 | -86,421,000 | 522,472,000 | 78,438,000 | 150,220,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-293,704,000
Investing CF
$19,992,000
Financing CF
$257,204,000
CapEx
$-10,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-07-12
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,179,935,000
Inventory
—
Receivables
$19,000,000
ST Investments
$375,844,000
EBIT TTM
$-361,179,000
Pretax Income TTM
$-341,622,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,766,000
EBITDA
$-353,180,000
Free Cash Flow
$-164,635,872
Enterprise Value
$2,219,534,336
Total Cash
$443,528,992
Total Debt
$58,143,000
Shares Out
103,781,683
Trailing EPS
$-3.46
Book Value
$3.88
ROE
-80.3%
ROA
-40.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 83,980,000 | -285,666,000 | -264,457,000 | 688,135,000 | 149,388,000 | 538,747,000 | -249,465,000 |
| Nov 2024 | 54,549,000 | -213,027,000 | -193,569,000 | 669,343,000 | 142,350,000 | 526,993,000 | -172,584,000 |
| Nov 2023 | 76,987,000 | -155,063,000 | -143,948,000 | 355,598,000 | 155,105,000 | 200,493,000 | -81,365,000 |
| Nov 2022 | 38,627,000 | -183,867,000 | -180,360,000 | 416,759,000 | 113,063,000 | 303,696,000 | -159,807,000 |
TTM Snapshot
Revenues TTM
$71,779,000
NetIncome TTM
$-295,280,000
OpCashFlow TTM
—
Assets (Latest)
$636,130,000
Forward EPS
$-1.07
Max Pain — expiry 2026-10-16
max pain strike: $24.00 · spot: $22.21 · call oi: 1,176 · put oi: 974
Expected Move to 2026-10-16:
±$3.34
(15.04%) —
implied range
$18.87 –
$25.55
· ATM straddle on $22.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | $39.60 | — |
| IRON | Disc Medicine, Inc. | $2.33B | $60.77 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $2.27B | $11.26 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.27B | $47.87 | — |
| BHC | Bausch Health Companies Inc. | $2.26B | $6.04 | — |
News headlines (Yahoo Finance, 1h cache)
Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?
2026-10-07 23:17 · Yahoo
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
2026-10-05 11:00 · Yahoo
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
2026-09-29 11:00 · Yahoo
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
2026-09-09 16:00 · Yahoo
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-01 12:00 · Yahoo
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
2026-08-20 11:00 · Yahoo
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
2026-08-10 16:44 · Yahoo
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins
2026-08-05 21:17 · Yahoo
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2026-08-04 05:00 · Yahoo
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo
2026-07-21 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.